ERBB2 and neoplasm: In contrast to radiolabeled trastuzumab, which was unable to accumulate in intracranial SKOV3 tumors, radiolabeled nanobody (225Ac DOTA 2Rs15d) demonstrated strong and targeted tumor uptake in HER2-positive brain lesions [77].